Peter Bean
Physician Assistant · Charleston, SCNPI 1336730654
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 286 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 25 manufacturers, the largest accounting for just 15.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $2,434 and has fallen 95.9% since, to $101 in 2025. Among physician assistant clinicians in SC with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 286 payments — averaging $18.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Supernus Pharmaceuticals, Inc.$808
- Teva Pharmaceuticals USA, Inc.$549
- Axsome Therapeutics, Inc.$445
- Otsuka America Pharmaceutical, Inc.$431
- Johnson & Johnson$333
- Alkermes, Inc.$286
- plus $2K from 19 others
What the payments were for
- Food & beverage$5,191100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Supernus Pharmaceuticals, Inc. | 35 | $808 |
| Teva Pharmaceuticals USA, Inc. | 30 | $549 |
| Axsome Therapeutics, Inc. | 25 | $445 |
| Otsuka America Pharmaceutical, Inc. | 26 | $431 |
| Johnson & Johnson | 14 | $333 |
| Alkermes, Inc. | 13 | $286 |
| AbbVie | 19 | $284 |
| Takeda Pharmaceuticals U.S.A., Inc. | 26 | $283 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 14 | $278 |
| Neurocrine Biosciences, Inc. | 20 | $275 |
| USWM, LLC | 13 | $270 |
| Indivior Inc. | 11 | $241 |
| Vanda Pharmaceuticals Inc. | 5 | $106 |
| Bausch Health US, LLC | 6 | $89 |
| Idorsia Pharmaceuticals US Inc | 4 | $85 |
| Almatica Pharma LLC | 4 | $76 |
| Merck | 5 | $71 |
| Lundbeck LLC | 4 | $66 |
| Noven Therapeutics, LLC | 4 | $60 |
| Braeburn Inc. | 2 | $46 |
| Avanir Pharmaceuticals, Inc. | 2 | $41 |
| Orexo US, Inc. | 1 | $19 |
| Corium, LLC | 1 | $18 |
| Sunovion Pharmaceuticals Inc. | 1 | $16 |
| Ironshore Pharmaceuticals Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,191 in reported general payments places this provider in the 90th percentile of 1,852 physician assistant providers in South Carolina.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 64 | $11,291 |
| Mirtazapine | 28 | $403 |
| Quetiapine Fumarate | 16 | $253 |
| Buspirone Hcl | 15 | $167 |
| Clonazepam | 13 | $158 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 15 | $158 |
| Trazodone Hcl | 11 | $150 |
| Bupropion XlBupropion Hcl | 12 | $137 |
| Alprazolam | 34 | $74 |
| Lorazepam | 11 | $70 |
| Duloxetine Hcl | 11 | $36 |
Paid to pharmacies, not to this prescriber.
Other physician assistant in Charleston
- Michael OvercashCharleston$210K
- Elizabeth HardingCharleston$28K
- Whitney PutillionCharleston$18K
- Corin JaynesCharleston$17K
- Karen ByrdCharleston$16K
- Colleen ManningCharleston$14K
- Kara GayCharleston$13K
- John RicheyCharleston$12K
- John HendrickCharleston$11K
- Keenan RosadoCharleston$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.